Trademark: 97470839
Word
B
Status Date
Thursday, February 8, 2024
Filing Date
Wednesday, June 22, 2022
Published for Opposition
Tuesday, January 17, 2023
5 Pharmaceuticals for use in the treatment of oncological, cardiological, dermatological, neurological, genetic, orthopedic and metabolic diseases and disorders
42 Pharmaceutical research and development services
BRIDGEBIO; BRIDGE BIO
Color is not claimed as a feature of the mark.
Feb 9, 2024
Notice Of Approval Of Extension Request E-Mailed
Feb 8, 2024
Sou Extension 2 Granted
Feb 8, 2024
Sou Extension 2 Filed
Feb 8, 2024
Sou Teas Extension Received
Aug 15, 2023
Notice Of Approval Of Extension Request E-Mailed
Aug 11, 2023
Sou Extension 1 Granted
Aug 11, 2023
Sou Extension 1 Filed
Aug 11, 2023
Sou Teas Extension Received
Mar 14, 2023
Noa E-Mailed - Sou Required From Applicant
Jan 17, 2023
Official Gazette Publication Confirmation E-Mailed
Jan 17, 2023
Published For Opposition
Dec 28, 2022
Notification Of Notice Of Publication E-Mailed
Dec 13, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Dec 13, 2022
Teas Change Of Correspondence Received
Dec 13, 2022
Teas Change Of Owner Address Received
Dec 13, 2022
Approved For Pub - Principal Register
Dec 11, 2022
Assigned To Examiner
Jul 12, 2022
Notice Of Design Search Code E-Mailed
Jul 11, 2022
New Application Office Supplied Data Entered
Jun 25, 2022
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24